Chemotherapy Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer ... Author: BeaconMedIC Added: 09/25/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 25, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Does radiation therapy play a role in gastric cancer adjuvant therapy? - No
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. David H. Ilson argues that peri-operative chemotherapy is the standard of care. Earn CME Credit for a related acti... Author: imedex Added: 09/07/2017 (Source: Oncology Tube)
Source: Oncology Tube - September 7, 2017 Category: Cancer & Oncology Source Type: podcasts

Women Have Superior Response to Esophageal Cancer Treatment Individualized and targeted treatment approaches based on genetics may improve outcomes
K. Robert Shen, MD of Mayo Clinic in Rochester reports that female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more like... Author: Cancer-News Added: 08/31/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2017 Category: Cancer & Oncology Source Type: podcasts

Median Survival Rate Nearly Doubles Combining Inotuzumab with Chemotherapy
Hagop M. Kantarjian, MD of MD Anderson Cancer Center's Department of Leukemia states the median survival rate nearly doubles combining Inotuzumab with chemotherapy for adult patients with relapsed o... Author: Cancer-News Added: 08/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 30, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/capecitabine
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that gemcitabine/capecitabine is the optimal adjuvant chemotherapy regimen for resected ... Author: imedex Added: 08/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Optimal adjuvant chemotherapy for resected pancreatic cancer - Gemcitabine/nab-paclitaxel
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that gemcitabine/nab-paclitaxel is the optimal adjuvant chemotherapy for resected pancreatic can... Author: imedex Added: 08/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Optimal neoadjuvant strategy in pancreatic cancer - Preoperative chemotherapy + radiation
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that preoperative chemotherapy plus radiation is the optimal neoadjuvant strategy for pan... Author: imedex Added: 08/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2017 Category: Cancer & Oncology Source Type: podcasts

Debate: Optimal neoadjuvant strategy in pancreatic cancer - Chemotherapy alone
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that chemotherapy alone is the optimal neoadjuvant strategy for pancreatic cancer. Earn CME C... Author: imedex Added: 08/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 23, 2017 Category: Cancer & Oncology Source Type: podcasts

Vyxeos Safety and Efficacy
Karen Smith, MD outlines the safety and efficacy of Vyxeos the newly approved chemotherapy for the treatment of adults with newly-diagnosed t-AML or AML-MRC. The FDA approval is based on data from... Author: Cancer-News Added: 08/04/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 4, 2017 Category: Cancer & Oncology Source Type: podcasts

OlympiAD: Olaparib versus Chemotherapy in HER2-Negative Metastatic Breast Cancer and a Germline BRCA Mutation
Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotligh... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Combining anti-PD-L1/PD-1 therapies with chemotherapy and targeted therapies in lung cancer treatment
Jack West, MD of Swedish Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted therapy for lung cancer treatment at the 2017 ASCO Annual Meeting... Author: obr Added: 06/23/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 23, 2017 Category: Cancer & Oncology Source Type: podcasts

The optimal duration of adjuvant chemotherapy in colon cancer
Leonard Saltz, MD of Memorial Sloan Kettering Cancer Center explains the optimal duration of adjuvant chemotherapy in colon cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Author: obr Added: 06/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2017 Category: Cancer & Oncology Source Type: podcasts

Gefinitib vs vinorelbine-cisplatin as adjuvant treatment in stage II-IIIA NSCLC with EGFR-activating mutation
Edward Kim, MD of Levine Cancer Institute discusses the use of gefitinib versus standard chemotherapy for patients with stage II-IIIA non-small cell lung cancer with an EGFR mutation. This was recorde... Author: obr Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts

How are anti-PD-L1/PD-1 therapies being combined with chemotherapy and targeted therapies in the treatment of lung cancer?
Edward Kim, MD of Levine Cancer Institute explains how anti-PD-L1 and PD-1 therapies are being combined with chemotherapy and targeted therapies in treating lung cancer at the 2017 ASCO Annual Meeting... Author: obr Added: 06/21/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2017 Category: Cancer & Oncology Source Type: podcasts

How does the side effect profile of abiraterone compare with the side effect profile fo chemotherapy?
Nancy Dawson, MD of Lombardi Cancer Center at Georgetown University Hospital discusses the difference in side effects between abiraterone and chemotherapy at the 2017 ASCO Annual Meeting in Chicago, I... Author: obr Added: 06/20/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 20, 2017 Category: Cancer & Oncology Source Type: podcasts